The 2016 Lasker-DeBakey Clinical Medical Research Award: Innovative hepatitis C virus(HCV) replicons leading to drug development for hepatitis C cure

作     者：Qinjian Zhao Ningshao Xia 

作者机构：State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics School of Public Health Xiamen University National Institute of Diagnostics and Vaccine Development in Infectious Diseases School of Life Sciences Xiamen University 

出 版 物：《Science China(Life Sciences)》 (中国科学（生命科学英文版）)

年 卷 期：2016年第59卷第11期

页      面：1198-1201页

核心收录：

学科分类：0710[理学-生物学] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：HCV Innovative hepatitis C virus replicons leading to drug development for hepatitis C cure The 2016 Lasker-DeBakey Clinical Medical Research Award 

摘      要：The 2016 Lasker-DeBakey Clinical Medical Research Award was given to three scientists working on different stages of the translational sciences on bringing a high efficacious therapy against hepatitis C virus （HCV） infection to a reality. An effective treatment of HCV chronic infection was developed, by a team led by Michael Sofia, using a prodrug approach and the drug PSI-7977 or Sofosbuvir was approved in 2013 less than 28 years after the initial discovery of HCV.